Published on 27 June 2023
Description:
Hold on to your human hats, everyone! In the latest edition of PharmaTimes we take a magical mystery tour through the mind-boggling maze of AI and what it means for healthcare, pharma and earthlings in general. Other intriguing content includes the normalising patient centricity, healthcare equity across the NHS and the future of life sciences in the UK.
Categories:
PharmaTimes28 articles from this collection:
Cover
2 - Pharmafocus
3 - From the editor
This month PharmaTimes presents Alantra’s annual ranking of the fastest growing pharma companies in the UK, and again there is much cause for celebration. As the analysis shows, a relentless focus on innovation and a determination to solve problems hindering patient outcomes are key traits that have helped those at the top shine in a sector that saw average growth of 33% in 2020.
4-5 - Contents
6 - NEWS: Treatments
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on the potential reclassification of two progestogen-only, oral contraceptive pills containing desogestrel: Lovima 75mcg and Hana 75mcg film-coated tablets.
7 - NEWS: NHS
8 - NEWS: Research
9 - NEWS: Conditions
10-11 - COVER STORY: Oh my, it’s AI!
12-13 - AI: AI on trial
14 - INTCROY
15 - WOMEN IN PHARMA: A whole new world
16 - THOUGHT LEADER: One true vision
17 - DIGITAL HEALTH: Releasing healthcare tech’s potential
18-19 - PATIENTS: Pump up the volume
20-21 - INDUSTRY FUTURE: Get cape. Wear cape. Fly?
22 - THOUGHT LEADERSHIP: Partnering for preventative medicine
23 - ICROY
24-25 - INCLUSION: Culture tours and the new mindset
26-28 - NHS: Balancing act
29 - AWARDS: BOBI Awards 2023
30-31 - PHARMA FUTURE: Succession
32-33 - DATA: Pharma’s market
34-35 - AI: Planets align
36-37 - Your moves
38 - AI: Welcome to the machine
39 - COMMUNICATIONS AWRDS
40 - FlyPharma Europe
PharmaTimes
PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.